Keywords: مهار کننده های پروتئازوم; Multiple myeloma; Second primary malignancies; Immunomodulatory drugs; Proteasome inhibitors; Plerixafor;
مقالات ISI مهار کننده های پروتئازوم (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهار کننده های پروتئازوم; Bortezomib; Daratumumab; Dexamethasone; Epigenetic aberrations; Immunomodulatory drugs; Lenalidomide; Microenvironment; P-glycoprotein; Proteasome inhibitors;
Keywords: مهار کننده های پروتئازوم; Proteasome inhibitors; Immunoproteasome; Constitutive proteasome; 3-HydroxyOxindolylalanine derivatives; Tryptophan oxidation;
Keywords: مهار کننده های پروتئازوم; AE; Adverse event; BIPN; Bortezomib-induced peripheral neuropathy; C-L; Caspase-like; CFZ; Carfilzomib; ChT-L; Chymotrypsin-like action; IRd; Ixazomib, lenalidomide, and dexamethasone; LG; Leaving group; MM; Multiple myeloma; MTD; Maximum tolerated dose;
Keywords: مهار کننده های پروتئازوم; proteasome inhibitors; multiple myeloma; bortezomib; ubiquitin-proteasome pathway;
Keywords: مهار کننده های پروتئازوم; Proteasome inhibitors; Azobenzenes; Photopharmacology;
Keywords: مهار کننده های پروتئازوم; Proteasome inhibitors; Heart failure; Myocardium; Multiple myeloma;
Keywords: مهار کننده های پروتئازوم; Carfilzomib; Proteasome inhibitors; Multiple myeloma; Coronary resistance; Vascular tone;
Keywords: مهار کننده های پروتئازوم; Cardiac amyloidosis; Multiple myeloma; TTR; Cardiotoxicity; Proteasome inhibitors; Immunomodulatory drugs;
Keywords: مهار کننده های پروتئازوم; multiple myeloma; immunomodulatory drugs; proteasome inhibitors; treatment; side effects;
Keywords: مهار کننده های پروتئازوم; Relapsed/refractory multiple myeloma; Treatment strategies; Immunomodulatory agents; IMiDs; Proteasome inhibitors; Outcomes; Health-related quality of life;
Keywords: مهار کننده های پروتئازوم; Anthracyclines; Deacetylase inhibitors; Drug resistance; Proteasome activity; Proteasome inhibitors;
Keywords: مهار کننده های پروتئازوم; Proteasome inhibitors; Non-peptide boronic acid; 1, 4-naphthoquinones; Docking studies;
Keywords: مهار کننده های پروتئازوم; Proteasome inhibitors; Phthalazinone; Triphenylphosphine; Drug design; Structure-activity relationship;
Keywords: مهار کننده های پروتئازوم; apoptosis; autophagy; bortezomib; proteasome inhibitors; solid tumors
Keywords: مهار کننده های پروتئازوم; Proteasome inhibitors; Natural products; Actinomycetes;
Keywords: مهار کننده های پروتئازوم; Proteasome inhibitors; Piperidine; Non-covalent; Anti-cancer; SARs;
Keywords: مهار کننده های پروتئازوم; Antibacterial; Anticandidal; Antioxidant; Nanoparticles; Proteasome inhibitors;
Keywords: مهار کننده های پروتئازوم; Heparanase; Chemotherapy; Multiple myeloma; Proteasome inhibitors; NF-κB; Roneparstat; HPSE; heparanase; (NF-κB); nuclear factor-kappa B; SDC1; syndecan-1; BTZ; bortezomib; CFZ; carfilzomib; HGF; hepatocyte growth factor; VEGF; vascular endothelial grow
Keywords: مهار کننده های پروتئازوم; Proteasome inhibitors; Non-covalent; Peptide scaffold; Docking studies; Virtual screening; AMC; 7-amino-4-methylcoumarin; ChT-L; chymotrypsin-like; DMSO; dimethylsulfoxide; HMBC; Heteronuclear multi-bond correlations; HSQC; Heteronuclear single-quantum co
Keywords: مهار کننده های پروتئازوم; Proteasome; Immunoproteasome; Proteolysis; Proteasome inhibitors; Domestic animals; Proteasome peptidase activities
Keywords: مهار کننده های پروتئازوم; Peripheral neurophathy; Proteasome inhibitors; Neurotoxicity; Bortezomib; Carfilzomib
Keywords: مهار کننده های پروتئازوم; Amides; Proteasome inhibitors; Non-covalent inhibitors; Docking studiesChT-L, chymotrypsin-like; T-L, trypsin-like; PGPH, post-glutamyl peptide hydrolyzing; C-L, caspase-like; DMSO, dimethyl sulfoxide; EDC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; H
Keywords: مهار کننده های پروتئازوم; Proteasome inhibitors; β-Amino acid; Epoxyketone; Anti-cancer; Drug design; SARs
Keywords: مهار کننده های پروتئازوم; AZ; antizyme; AZBE; antizyme-binding element; AZIN; antizyme inhibitor; ERGIC; endoplasmic reticulum-Golgi intermediate compartment; ODC; ornithine decarboxylase; GDT_TS; global distance test total score; HA; hemagglutinin; HEK; human embryonic kidney; PA
Keywords: مهار کننده های پروتئازوم; Immunomodulatory agents; Proteasome inhibitors; Maintenance therapy; Reduced-intensity conditioning;
Keywords: مهار کننده های پروتئازوم; Multiple myeloma; Relapsed/refractory; Complete remission; Prognostic factors; Immunomodulatory drugs; Proteasome inhibitors; Emerging agents;
Keywords: مهار کننده های پروتئازوم; Peptidomimetic boronates; Proteasome inhibitors; Docking studies; ChT-L; chymotrypsin-like; T-L; trypsin-like; PGPH; post-glutamyl peptide hydrolyzing; DMSO; dimethyl sulfoxide; DMF; dimethylformamide; Pd2(dba)3; tris(benzylideneacetone)dipalladium; EDC;
Discovery of novel 20S proteasome inhibitors by rational topology-based scaffold hopping of bortezomib
Keywords: مهار کننده های پروتئازوم; Proteasome inhibitors; Topology-based; Scaffold hopping; Bortezomib;
Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors
Keywords: مهار کننده های پروتئازوم; Curcumin derivatives; Proteasome inhibitors; α-Amino boronic acid; Antitumor activity; Subunit selectivity;
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate rece
Keywords: مهار کننده های پروتئازوم; Alefacept; Fingolimod; Infection; Ipilimumab; Natalizumab; Nivolumab; Pembrolizumab; Progressive multifocal leukoencephalopathy; Proteasome inhibitors; Vedolizumab;
Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors
Keywords: مهار کننده های پروتئازوم; Proteasome inhibitors; Cystargolides; Structure-activity relationship; Beta-lactones; Cytotoxicity;
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma
Keywords: مهار کننده های پروتئازوم; Clinical trial; DLBCL; Histone deacetylase inhibitor; MCL; Proteasome inhibitors;
BaxÎ2 sensitizes colorectal cancer cells to proteasome inhibitor-induced cell death
Keywords: مهار کننده های پروتئازوم; BaxÎ2; Cell death; Proteasome inhibitors; Cancer therapy; Bortezomib; Carfilzomib;
In vitro and in vivo studies of gold(I) azolate/phosphane complexes for the treatment of basal like breast cancer
Keywords: مهار کننده های پروتئازوم; Gold compounds; Phosphane; Breast cancer; Anticancer agents; Apoptosis; Proteasome inhibitors;
Deubiquitylating enzymes as cancer stem cell therapeutics
Keywords: مهار کننده های پروتئازوم; Protein-IPSC; protein-induced pluripotent stem cells; CSCs; cancer stem cells; DUBs; deubiquitylating enzymes; ESCs; embryonic stem cells; PTMs; post-translational modifications; AML; acute myelogenous leukemia; USP/UBP; ubiquitin-specific processing prot
Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either Agent Alone
Keywords: مهار کننده های پروتئازوم; Post-transplantation cyclophosphamide; Proteasome inhibitors; Ixazomib; Graft-versus-host disease;
MożliwoÅci leczenia indukcyjnego chorych na szpiczaka plazmocytowego kwalifikujÄ
cych siÄ do chemioterapii wysokodawkowanej wspomaganej autologicznÄ
transplantacjÄ
komórek krwiotwórczych a aktualne zalecenia Polskiej Grupy Szpiczakowej
Keywords: مهار کننده های پروتئازوم; szpiczak plazmocytowy; inhibitory proteasomu; immunomodulatory; autotransplantacja komórek krwiotwórczych.; Plasma cell myeloma; Proteasome inhibitors; Immunomodulators; Stem cell autotransplantation.;
Original ArticleIdentification of a synergistic combination of Smac mimetic and Bortezomib to trigger cell death in B-cell non-Hodgkin lymphoma cells
Keywords: مهار کننده های پروتئازوم; Smac mimetics; Cell death; Necroptosis; B-cell non-Hodgkin lymphoma; IAP proteins; Proteasome inhibitors; ALL; acute lymphoblastic leukemia; CI; combination index; cIAP; cellular IAP; DLBCL; diffuse large B-cell lymphoma; FCS; fetal calf serum; FSC/SCC; f
Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors
Keywords: مهار کننده های پروتئازوم; Proteasome inhibitors; Piperazine or piperidine; Non-covalent; Peptidyl derivatives; Anti-cancer;
Discovery of a potent and highly specific β2 proteasome inhibitor from a library of copper complexes
Keywords: مهار کننده های پروتئازوم; Proteasome inhibitors; Schiff base; Copper complex; Drug design; Structure-activity relationships;
Concise review â Treatment of multiple myeloma in the very elderly: How do novel agents fit in?
Keywords: مهار کننده های پروتئازوم; Multiple myeloma; Elderly patients; Proteasome inhibitors; IMiDs; Geriatric assessment;
NF-κB dysregulation in multiple myeloma
Keywords: مهار کننده های پروتئازوم; Myeloma; NF-kappaB; Microenvironment; Stromal cells; Proteasome inhibitors;
Endocytosis of human immunodeficiency virus 1 (HIV-1) in astrocytes: A fiery path to its destination
Keywords: مهار کننده های پروتئازوم; HIV-1 brain; HIV-1 persistence; Lysosomotropic drugs; Chloroquine; Proteasome inhibitors; LSP1; Rab; Rev; Tat
Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome
Keywords: مهار کننده های پروتئازوم; Proteasome inhibitors; Non-covalent; Linear peptides; Selectivity; Fragment-based approach;
Synthesis, characterization and anticancer activity of two ternary copper(ÐÐ) Schiff base complexes
Keywords: مهار کننده های پروتئازوم; QQHJOEZBDSMQRV-ANIRPTSXSA-J; Schiff base; copper(II) complex; crystal structure; anticancer activity; proteasome inhibitors;
Optimizing the Treatment of Patients With Multiple Myeloma and Renal Impairment
Keywords: مهار کننده های پروتئازوم; Bendamustine; Bisphosphonates; Immunomodulatory drugs; Proteasome inhibitors; Stem cell transplantation;
Novel Drug Combinations for the Management of Relapsed/Refractory Multiple Myeloma
Keywords: مهار کننده های پروتئازوم; Histone deacetylase inhibitors; Immunomodulatory agents; Monoclonal antibodies; Proteasome inhibitors; Treatment
Bortezomib in Multiple Myeloma: A Practice Guideline
Keywords: مهار کننده های پروتئازوم; Bortezomib; multiple myeloma; practice guideline; proteasome inhibitors;
Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors
Keywords: مهار کننده های پروتئازوم; Peptidomimetic boronates; Proteasome inhibitors; Docking studiesChT-L, chymotrypsin-like; T-L, trypsin-like; PGPH, post-glutamyl peptide hydrolyzing; C-L, caspase-like; DMSO, dimethyl sulfoxide; EDC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; HOBt, N-